| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3328126 | Acta Haematologica Polonica | 2015 | 7 Pages |
Abstract
Obinutuzumab (also known as GA101) is a humanized, glycoengineered type II monoclonal antibody targeted against CD20. Studies in animal models suggest that obinutuzumab shows superior efficacy, as compared with rituximab, by inducing direct cell death and increased antibody dependent cellular cytotoxicity activity with less complement – dependent cytotoxicity. In clinical trials, obinutuzumab in monotherapy and in combination with other agents showed an activity against chronic lymphocytic leukemia, even in rituximab – resistant patients. This article presents the review of current publications concerning the mechanism of action, efficacy and safety of obinutuzumab.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Agnieszka Karczmarczyk, Krzysztof Giannopoulos,